Free Republic

Convalescent plasma generated great enthusiasm in the earliest days of the coronavirus disease The PLACID Trial was a rigorous randomized controlled study on a topic of enormous global importance In prespecified, intention-to-treat analyses, the PLACID Trial investigators found no net benefit associated with convalescent plasma in patients admitted to hospital with moderate covid-19 there was no net clinical benefit to patients

The most comprehensive national study to date has found that convalescent plasma appears to be safe to use on COVID-19 patients, a promising development in the race to find a treatment for the deadly virus. But the study didn't determine whether the treatment works. A team of more than 5,000 doctors from over 2,000 hospitals and laboratories have been testing the experimental therapy, which involves transfusing the antibody-rich blood serum of recovered COVID-19 patients into people who are battling the illness. Of the 5,000 seriously ill patients who received blood plasma transfusions for the study, fewer than 1 percent experienced...